Inhaled drug could treat rare cystic fibrosis mutations
SpliSense has demonstrated in human-derived cells that it can generate a functioning protein to replace one that is defective in 20% of CF cases.
SpliSense has demonstrated in human-derived cells that it can generate a functioning protein to replace one that is defective in 20% of CF cases.
For the more than 35 million Americans suffering from diseases of the airways this could be a breath of fresh air.